LEGENDNCT07917104
Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Recurrence-Free Survival (RFS)
Timeframe: From randomization through the end of the two-year postoperative follow-up.
Secondary (10)
Overall Survival (OS)
Postoperative ctDNA Methylation Positivity Rate
Agreement Between ctDNA Methylation Status and Imaging Findings
Lead Time From ctDNA Methylation Positivity to Imaging-Confirmed Recurrence
Secondary No Evidence of Disease (NED) Conversion Rate
Show 5 moreShow less
ctDNA Methylation Clearance Rate
Time to ctDNA Methylation Clearance
ctDNA Methylation Test Reporting Turnaround Time
Patient-reported Quality of Life
Incremental Cost-Effectiveness Ratio (ICER)
Arms and interventions
ctDNA Methylation-Guided TreatmentExperimental
Conventional TreatmentActive comparator
Combination products: Circulating Tumor DNA Methylation Testing
Other: Conventional Postoperative Treatment Strategy
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China